A Meta-Analysis and Indirect Comparison of Endothelin A Receptor Antagonist for Castration-Resistant Prostate Cancer

doi:10.1371/journal.pone.0133803

CORC > 兰州大学 > 兰州大学 > 第二临床医学院 > 期刊论文

	A Meta-Analysis and Indirect Comparison of Endothelin A Receptor Antagonist for Castration-Resistant Prostate Cancer
	Qi, P; Chen, M; Zhang, LX; Song, RX; He, ZH; Wang, ZP; Wang, ZP (reprint author), Lanzhou Univ, Hosp 2, Inst Urol, Lanzhou 730030, Peoples R China.
刊名	PLOS ONE
	2015-07-20
卷号	10 期号:7
ISSN号	1932-6203
DOI	10.1371/journal.pone.0133803
文献子类	Article
英文摘要	Background Endothelin A (ET-A) receptor antagonists including zibotentan and atrasentan, have been suggested as a treatment for castration-resistant prostate cancer (CRPC). Our aim was to conduct a meta-analysis and indirect comparison to assess the efficacy and safety of ET-A receptor antagonists for treatment of CRPC. Methods We systematically searched PubMed, EMBASE, the Cochrane Library, and Web of Science from inception to November 2014 to identify randomized controlled trials (RCTs) which assessed ET-A receptor antagonists for treatment of CRPC. Meta-analysis was conducted by STATA version 12.0 software. Results Eight RCTs were identified, involving 6,065 patients. The results of direct comparison showed that compared with placebo, there was no statistically significant difference in the improvement of progression-free survival (PFS), overall survival (OS), time to disease progression (TTP), and total adverse events (AEs) with ET-A receptor antagonist treatment for CRPC. The results of ET-A receptor antagonists plus docetaxel versus docetaxel alone were similar. The indirect comparisons showed that there were no significant differences between zibotentan plus docetaxel versus atrasentan plus docetaxel when compared with docetaxel alone or zibotentan versus atrasenta compared with placebo in the improvement of PFS, OS, TTP, and total adverse events. Conclusions There were no significant benefits for ET-A receptor antagonists with or without docetaxel in the improvement of PFS, OS, TTP, and overall AEs. And there were no significant differences between zibotentan and atrasentan. Single-agent docetaxel should remain as one of the standard treatments.
学科主题	Science & Technology - Other Topics
出版地	SAN FRANCISCO
语种	英语
WOS记录号	WOS:000358546400120
内容类型	期刊论文
源URL	[http://ir.lzu.edu.cn/handle/262010/179378]
专题	第二临床医学院_期刊论文
通讯作者	Wang, ZP (reprint author), Lanzhou Univ, Hosp 2, Inst Urol, Lanzhou 730030, Peoples R China.
推荐引用方式 GB/T 7714	Qi, P,Chen, M,Zhang, LX,et al. A Meta-Analysis and Indirect Comparison of Endothelin A Receptor Antagonist for Castration-Resistant Prostate Cancer[J]. PLOS ONE,2015,10(7).
APA	Qi, P.,Chen, M.,Zhang, LX.,Song, RX.,He, ZH.,...&Wang, ZP .(2015).A Meta-Analysis and Indirect Comparison of Endothelin A Receptor Antagonist for Castration-Resistant Prostate Cancer.PLOS ONE,10(7).
MLA	Qi, P,et al."A Meta-Analysis and Indirect Comparison of Endothelin A Receptor Antagonist for Castration-Resistant Prostate Cancer".PLOS ONE 10.7(2015).